Thomas DesRosier

Thomas DesRosier

General Counsel at SERES THERAPEUTICS, INC.

Net worth: 58 223 $ as of 31/05/2026

71 year
Health Technology
Consumer Services
Process Industries

Profile

Thomas J.
DesRosier
is currently Director at Avanir Pharmaceuticals, Inc., Director at Optimer Pharmaceuticals LLC since 2013, and Chief Legal Officer & Executive Vice President at Seres Therapeutics, Inc. since 2016.
Former positions include Director at Trius Therapeutics, Inc.; Assistant General Counsel-Patents at Wyeth LLC; Chief Patent Counsel & Vice President at Genetics Institute LLC; Secretary, Chief Legal & Administrative Officer at ARIAD Pharmaceuticals, Inc. from 2015 to 2016; Secretary, Chief Legal & Administrative Officer at Cubist Pharmaceuticals LLC from 2013 to 2015; Chief Legal Officer, SVP & General Counsel at Genzyme Corp.
from 1999 to 2011; Senior Vice President & General Counsel at Sanofi from 2011 to 2013; and Principal roles at Wyeth Pharmaceuticals LLC, Lantheus Medical Imaging, Inc., and Dupont De Nemours & Co., Inc. Education includes undergraduate studies at the University of Vermont and graduate studies at Wake Forest University School of Law.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
18/05/2026 7,954 ( 0.08% ) 58 223 $ 31/05/2026

Thomas DesRosier active positions

CompaniesPositionStart
SERES THERAPEUTICS, INC. General Counsel 16/05/2016
Director/Board Member 24/10/2013

Former positions of Thomas DesRosier

CompaniesPositionEnd
ARIAD PHARMACEUTICALS, INC. Chief Administrative Officer 01/01/2016
CUBIST PHARMACEUTICALS INC Chief Administrative Officer 22/01/2015
SANOFI General Counsel 01/01/2013
General Counsel 01/01/2011
AVANIR PHARMACEUTICALS INC Director/Board Member -
See the detail of Thomas DesRosier's experience

Training of Thomas DesRosier

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

76

1st degree connections

15

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies15

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Process Industries

Health Technology

Consumer Services

  1. Stock Market
  2. Insiders
  3. Thomas DesRosier
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!